Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes
Authors:
- 1 July 2021
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 4 (7) , e2115991
Abstract
Most younger patients with acute myeloid leukemia (AML) can achieve complete remission (CR) with induction chemotherapy.1 After CR, further postremission treatment (PRT) would be necessary to prevent relapse.2 Postremission treatment usually consists of either a stem cell transplant (SCT) or cytarabine-based consolidation chemotherapy. Allogeneic SCT (allo-SCT) is generally accepted as the most effective PRT to prevent relapse, but it has relatively high rates of transplant-related mortality.3 Autologous SCT (auto-SCT) and chemotherapy carry a lower risk of transplant-related mortality compared with allo-SCT.4 However, this lower risk of transplant-related mortality is offset by a higher risk of relapse owing to the lack of a graft-vs-leukemia effect and the potential infusion of leukemia cells in grafts.5,6 Currently, decisions for PRT depend mainly on risk stratification based on cytogenetics and molecular markers,2,7 but it remains controversial, particularly for patients with intermediate-risk AML (IR-AML).3-6,8-13 For instance, some studies have suggested that a survival benefit is associated with the use of allo-SCT in patients with IR-AML,3,5,6 whereas other studies have showed that auto-SCT or chemotherapy had no significant survival differences compared with allo-SCT.4,12,13 Thus, these studies highlight the need to find additional factors associated with survival outcomes that optimize PRT choices for patients with IR-AML.Keywords
This publication has 49 references indexed in Scilit:
- MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trialBlood, 2013
- T-Cell–Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor TransplantationJournal of Clinical Oncology, 2013
- Superior transplantation outcomes of 8/8‐matched unrelated donors as well as matched siblings to autologous transplantation for acute myeloid leukemia with intermediate cytogenetics in first remissionEuropean Journal of Haematology, 2013
- Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter studyJournal of Hematology & Oncology, 2013
- Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaJournal of Clinical Oncology, 2011
- Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemiaBlood, 2010
- Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete RemissionJAMA, 2009
- Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia RegistryBlood, 2009
- The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemiaLeukemia, 2006
- Autologous or Allogeneic Bone Marrow Transplantation Compared with Intensive Chemotherapy in Acute Myelogenous LeukemiaNew England Journal of Medicine, 1995